ZA941812B - Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 - Google Patents

Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Info

Publication number
ZA941812B
ZA941812B ZA941812A ZA941812A ZA941812B ZA 941812 B ZA941812 B ZA 941812B ZA 941812 A ZA941812 A ZA 941812A ZA 941812 A ZA941812 A ZA 941812A ZA 941812 B ZA941812 B ZA 941812B
Authority
ZA
South Africa
Prior art keywords
tumor rejection
rejection antigen
hla
nucleic acid
acid sequence
Prior art date
Application number
ZA941812A
Other languages
English (en)
Inventor
Vincent Brichard
Van Aline Pel
Catia Traversari
Thomas Wolfel
De Etienne Plaen
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of ZA941812B publication Critical patent/ZA941812B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA941812A 1993-03-18 1994-03-15 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 ZA941812B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/032,978 US5620886A (en) 1993-03-18 1993-03-18 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Publications (1)

Publication Number Publication Date
ZA941812B true ZA941812B (en) 1994-10-13

Family

ID=21867896

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA941812A ZA941812B (en) 1993-03-18 1994-03-15 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Country Status (17)

Country Link
US (2) US5620886A (xx)
EP (1) EP0690675B1 (xx)
JP (1) JP3433322B2 (xx)
CN (1) CN1072719C (xx)
AT (1) ATE258379T1 (xx)
AU (1) AU675707B2 (xx)
CA (1) CA2158446C (xx)
DE (2) DE69433518D1 (xx)
DK (1) DK0690675T5 (xx)
ES (1) ES2210252T3 (xx)
FI (1) FI954360A0 (xx)
NO (1) NO953601L (xx)
NZ (1) NZ263348A (xx)
PT (1) PT690675E (xx)
TW (1) TW442568B (xx)
WO (1) WO1994021126A1 (xx)
ZA (1) ZA941812B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
EP1630229B1 (en) 1994-04-22 2013-04-03 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US5674749A (en) * 1996-03-26 1997-10-07 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof
EP0910646A1 (en) * 1996-06-25 1999-04-28 The Ludwig Institute for Cancer Research Brain glycogen phosphorylase cancer antigen
EP1961820B1 (en) 1997-01-27 2012-11-28 Ludwig Institute for Cancer Research Ltd Vaccine composition comprising LAGE-1 tumor associated nucleic acids or LAGE-1 polypeptides
US5879892A (en) 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
JP2002500891A (ja) * 1998-01-26 2002-01-15 ジェンザイム・コーポレーション 抗原特異細胞、これらの細胞の生成方法及びその使用法
US6245525B1 (en) 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US7001999B1 (en) 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
EP1222274A2 (en) 1999-10-19 2002-07-17 Ludwig Institute For Cancer Research Mage-a12 antigenic peptides and uses thereof
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
JP5166025B2 (ja) * 2004-06-17 2013-03-21 マンカインド コーポレイション エピトープアナログ
KR101076578B1 (ko) 2004-06-23 2011-10-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 2입자 착물을 이용한 생물학적 분자의 검출을 위한 방법 및조성물
JP2008526760A (ja) 2004-12-29 2008-07-24 マンカインド コーポレイション 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用
US7999088B2 (en) 2005-06-17 2011-08-16 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
MX2007015951A (es) * 2005-06-17 2008-03-07 Mannkind Corp Analogos de epitopes.
CN101687020A (zh) 2005-06-17 2010-03-31 曼康公司 用于癌症的多价引发-和-增强免疫治疗剂
US8088379B2 (en) * 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
CA2688061A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
NZ585556A (en) 2007-11-07 2012-07-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2011050344A2 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
US9169325B2 (en) 2010-04-13 2015-10-27 Celldex Therapeutics, Inc. Antibodies that bind human CD27 and uses thereof
KR102204937B1 (ko) 2014-06-06 2021-01-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
US20180237534A1 (en) 2015-05-29 2018-08-23 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
KR102414558B1 (ko) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. 인간 cd40에 결합하는 효능성 항체 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells

Also Published As

Publication number Publication date
JP3433322B2 (ja) 2003-08-04
AU675707B2 (en) 1997-02-13
NO953601L (no) 1995-10-31
EP0690675A4 (en) 1998-12-23
NZ263348A (en) 1996-06-25
DE69433518T2 (de) 2004-06-24
JPH08507693A (ja) 1996-08-20
EP0690675B1 (en) 2004-01-28
US5620886A (en) 1997-04-15
EP0690675A1 (en) 1996-01-10
DE69433518T4 (de) 2009-07-23
CA2158446A1 (en) 1994-09-29
DK0690675T3 (da) 2004-06-01
DK0690675T5 (da) 2008-11-17
CA2158446C (en) 2009-01-06
ATE258379T1 (de) 2004-02-15
ES2210252T3 (es) 2004-07-01
FI954360A (fi) 1995-09-15
AU6399394A (en) 1994-10-11
TW442568B (en) 2001-06-23
WO1994021126A1 (en) 1994-09-29
CN1093406A (zh) 1994-10-12
FI954360A0 (fi) 1995-09-15
US5854203A (en) 1998-12-29
CN1072719C (zh) 2001-10-10
NO953601D0 (no) 1995-09-13
PT690675E (pt) 2004-06-30
DE69433518D1 (de) 2004-03-04

Similar Documents

Publication Publication Date Title
ZA941812B (en) Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
ZA944196B (en) Isolated peptides which form complexes with MHC molecule HLA-C-clone 10 and uses thereof
CA2223694A1 (en) Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
EP1135532A4 (en) FLUORESCENT PROTEINS BELONGING TO NON-BIOLUMINESCENT SPECIES OF THE ANTHOZOA CLASS, GENES ENCODING THE SAME AND USES THEREOF
ZA958039B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
HUP9801608A2 (hu) A 11. típusú humán papillomavírusból származó L1-fehérjét kódoló szintetikus HPV6/11-L1-hibrid-DNS
EA200200565A1 (ru) Применение клеток, трансфицированных днк, кодирующей лиганд мнс класса ii, и способ получения таких клеток
FI971609A (fi) Menetelmä 4a,5,9,10,11,12-heksahydro-6H-bentsofuro-(3a,3,2-ef)(2)-bentsatsepiinijohdannaisten valmistamiseksi
ES2193241T3 (es) Nuevas n-2-oxo2.3.4.5-tetrajodrp-1h-1,5-benzodiazepin-3-il)-3-amidas.
EP0142335A3 (en) Lactam containing compounds
HK1008228A1 (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen
NO970030L (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
HUT47136A (en) Process for producing cyclic peptides with anticoagulant effect
FR2575466B1 (fr) Nouveaux complexes de silicium hexacoordines, leur procede de preparation et leur application
EP0342989A3 (en) Polymaleimide compounds and process for the preparation thereof
FR2681069B1 (fr) Nouveau procede de preparation de l'hydrocortisone et nouveaux intermediaires.
EP0179412A3 (en) Antigenic peptide compounds
EP0232027A3 (en) N-carboxyalkyl compounds
OA09197A (fr) "Peptides SDK, leur procédé de préparation ainsi que des compositions thérapeutiques en contenant".
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
EA200000705A1 (ru) Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов
IT1180220B (it) Miscela di composti diastereoisomeri, ottenuti da (-)-5-(1-idrossi-1-metiletil)-2-metil-2-cicloesen-1-one, avente attivita' mucosecretolitica, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono
EP1122245A3 (en) 2-Amino-benzoxazinones for the treatment of viral infections
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.